3.25
+3.50%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Entera Bio
From its filings with the US Securities and Exchange Commission
Entera Bio is based in Jerusalem and is incorporated in Israel. Its shares trade on Nasdaq under the ticker ENTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $42,000 and a net loss of $11.4m. At that date it held total assets of $16.0m and shareholders' equity of $13.1m.
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap. From a technical standpoint, oral delivery of peptides and therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream. We leverage our N-Tab® platform, which is designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream.
Our most advanced product candidate, EB613 (oral teriparatide, or oral PTH[1-34]), is being developed as the first oral, osteoanabolic (bone building) tablet treatment for osteoporosis. EB613 is being developed under a 505(b)(2) application to the listed drug, Forteo® (teriparatide SC injection, Eli Lilly), which was first approved by the FDA in 2002 for the treatment of postmenopausal women with osteoporosis at high risk of fracture and later indicated for men with osteoporosis and osteoporosis associated with sustained systemic glucocorticoid therapy.
Quoted from its 10-K, filed 27 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Jun 2018
- Employees
- 20
- Website
- enterabio.com ↗
- Head office
- KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, 9112002
- Incorporated in
- L3
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Geno GermanoIndependent Chairman of the Board
- Ms. Miranda ToledanoChief Executive Officer, Director, since 2018$69,021
- Ms. Dana Yaacov-GarbeliChief Financial Officer
- Dr. Hillel GalitzerChief Operating Officer$640,000
- Mr. Ramesh RatanChief Financial Officer - United States
- Dr. Arthur SantoraChief Medical Officer$389,000
- Dr. Roger GarceauDirector, since 2016$90,000
- Mr. Sean EllisIndependent Director$65,586
- Mr. Yonatan MalcaIndependent Director$57,891
- Mr. Ron MayronIndependent Director$46,488
- Mr. Steven RubinIndependent Director
- Ms. Haya TaitelIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proprietary oral drug delivery technology, based on its proprietary E-Poly technology, provides a competitive advantage by improving the oral absorption of certain drugs.
- Strong intellectual property portfolio with patents covering its drug delivery technologies, offering protection and potential licensing opportunities.
- Collaborations and partnerships with reputable pharmaceutical companies, enhancing research and development capabilities, as well as enabling potential commercialization opportunities.
Weaknesses
- Limited product pipeline, with a focus on a select few candidates, may hinder future growth and diversification.
- Reliance on external funding sources for ongoing research and development, which can be challenging to secure or may result in dilution for existing shareholders.
- Limited commercialization experience and infrastructure, which could pose challenges when bringing products to market.
Opportunities
- Growing demand for improved oral drug delivery technologies, driven by the need for patient convenience, potential cost savings, and enhanced therapeutic outcomes.
- Potential partnerships and collaborations with pharmaceutical companies seeking to enhance the delivery of their drug candidates.
- Expansion into new therapeutic areas or applications of its drug delivery technology, broadening the addressable market.
Threats
- Intense competition in the oral drug delivery sector from established players and emerging technologies, which may limit market share and pricing power.
- Regulatory challenges and uncertainties, including potential delays in approvals, compliance requirements, and changing regulations impacting drug delivery technologies.
- Market volatility and economic uncertainties, which could impact funding availability and investor sentiment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.